Please check your email for the verification action. You may continue to use the site and you are now logged in, but you will not be able to return to the site in future until you confirm your email address.
Aims. The purpose of the present study was to evaluate the impact of
intravenous tranexamicacid on the reduction of blood loss, transfusion
rate, and early post-operative clinical outcome in total shoulder
arthroplasty. Patients and Methods. A randomised, placebo-controlled trial which included 54 patients
undergoing unilateral primary stemless anatomical or stemmed reverse
total shoulder arthroplasty was undertaken. Patients received either
100 ml saline (placebo, n = 27), or 100 ml saline together with
1000 mg of tranexamicacid (TXA, n = 27) intravenously prior to
skin incision and during wound closure. Peri-operative blood loss
via an intra-articular drain was recorded and total blood loss was
calculated. The post-operative transfusion rate was documented.
Assessment of early clinical parameters included the visual analogue
scale for pain (VAS), documentation of haematoma formation and adverse events. Results. Mean peri-operative blood drainage (placebo: 170 ml versus TXA:
50 ml, p = 0.001) and calculated mean total blood loss (placebo:
1248.2 ml versus TXA: 871.0 ml, p = 0.009) were
significantly lower in the TXA group. No transfusions were necessary
during the study period in either group. Mean VAS for pain significantly
decreased from pre-operative (VAS 7) to the early post-operative
period (VAS 1.7, p <
0.001). Significant differences regarding
mean post-operative pain between placebo (VAS 2.0) and TXA (VAS
1.3) were detected (p = 0.05). The occurrence of haematomas was
significantly more frequent in the placebo (59.3%, n = 16) than
in the TXA group (25.9%, n = 6, p = 0.027). Whereas only mild haematomas
developed in the TXA group, in the placebo group a total of 22.2%
(n = 6) developed either moderate or severe haematomas. No adverse
events associated with administration of TXA occurred. Conclusion. Intravenous administration of TXA successfully reduced mean peri-operative
blood drainage, total estimated blood loss, pain during the first
post-operative days, and haematoma formation in total shoulder arthroplasty. Cite this article: Bone Joint J 2017;99-B:1073–9